The Wolverine stack has found a new demographic: dogs. Business Insider reported today that a growing number of pet owners are administering BPC-157 and TB-500 — the healing-focused pairing the community calls the Wolverine stack — to aging and injured dogs — which BI reports can cost under $100 a month, against vet bills its subjects put in the thousands.
The trend did not appear from nowhere. Per BI's reporting, interest surged after podcaster Andrew Huberman posted to his 1.8 million X followers in July that he was hearing from "many people" getting "amazing results" using BPC-157 in aging and injured dogs. Men's Health had already documented owners adding BPC-157 to dog food back in April. What was a fringe experiment is now a reported movement with its own influencer dogs, dedicated pet-peptide brands, and a veterinary community asking where the guardrails are.
Research-context information only. BPC-157, TB-500, and KPV are research peptides. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
No peptide discussed here holds a veterinary marketing authorization, and there is no established canine dosage for any of them — decisions about an animal's care belong with a licensed veterinarian.
What Business Insider Reported
The BI story follows three owners across the income spectrum, and the details sketch the whole market in miniature.
The budget case. Ryan Samluk, a 29-year-old construction project manager in Dallas, faced a vet estimate of thousands of dollars in diagnostics plus arthritis injections at $200 per dose for Finley, his 11-year-old Australian-German Shepherd mix with a bad sprain. Instead he spent about $160 on a month of research peptides — a combination of KPV, marketed for inflammation control, and BPC-157. He told BI he scaled the dose down from human community protocols by body weight, bought from vendors friends had recommended for their own use, and watched a dog that could barely walk return to running around the yard within a week. He also acknowledged the obvious: "It felt like I was playing God."
The optimizer case. Michael Morelli, a Florida personal trainer, put his 14-year-old pit terrier Choo Choo on low-dose BPC-157 and TB-500 about a year ago — starting, per his account, at 500 micrograms and gradually escalating to 2 milligrams while watching for side effects. Choo Choo's regimen now spans two house-call vets, heavy-metal testing, red light therapy, physical therapy, and testosterone replacement — Morelli calls him the "most measured and optimized dog in the world," a nod to Bryan Johnson. After the Huberman post, Morelli's following exploded; he now runs a canine peptide brand called Pawgen and is promoting a Choo Choo meme coin to fund a pet rescue.
The luxury case. Sam Cheow, a beauty-industry executive, folds low-dose Wolverine stack injections into a wellness routine for his four Norwich terriers that costs thousands per year and includes caviar, collagen, and curated supplements. "I'm not using 20 cherries. I'm using a very low dosage," he told BI.
The common thread: every one of these owners experimented on themselves first. As Samluk put it, "If I'm happy to put them in my own body, I'm happy to give them to my dog."
What the Animal Research Actually Shows
There is an irony at the center of this story: BPC-157 and TB-500 built their reputations almost entirely on animal data — just not on companion-dog trials.
BPC-157's soft-tissue evidence base is rodent work. The most-cited study, Chang et al. in the Journal of Applied Physiology (PMID 21030672), found the peptide accelerated tendon-explant outgrowth and fibroblast migration in a rat Achilles model. Thymosin beta-4 — the parent molecule TB-500 is fragment-derived from — has a published review of animal studies (PMID 20536453) documenting accelerated dermal healing, reduced inflammation, and improved cell migration across multiple injury models. The full picture for each compound is in our BPC-157 benefits and TB-500 benefits breakdowns.
What does not exist: a single controlled trial of either peptide in client-owned dogs, any canine pharmacokinetic data, or any species-specific safety file. Dr. Kate Elden, chief medical officer at the online veterinary service Dutch, told BI the questions keep coming — "If people are on a Wolverine stack themself, they're asking if they should do it for their dog" — while noting a compound "might be processed or metabolized differently in a different species."
The sharpest scientific caution in the piece came from Celine Halioua, CEO of Loyal, the startup running FDA-track longevity drugs for dogs. Because BPC-157 appears to stimulate angiogenesis — blood-vessel growth, part of how wounds heal — she called its theoretical potential to feed existing tumors a "dealbreaker" for her, while adding that owners who proceed anyway should work with a vet to monitor for invisible side effects and use a reputable manufacturer. She also left the door open: "I hope someone uses the anecdotal data to develop a safe + optimized version, if the biology does indeed work! We need better OA [osteoarthritis] drugs for dogs."
The Regulatory Backdrop
Both compounds in Samluk's protocol sit inside a live human-side regulatory story. BPC-157 and KPV were among the peptides an FDA advisory committee shortlisted for compounding eligibility in July — the panel voted to advance seven peptides toward 503A pharmacy access. Neither is approved for human use today, and BI's reporting describes no veterinary approval pathway for either compound; the FDA-track canine program it cites is Loyal's separate longevity drug, which has nothing to do with gray-market peptides.
That leaves pet peptide use exactly where human research-peptide use sits: research-use-only vials, no approved indication, and quality that varies seller to seller.
What This Means for Peptide Buyers
The compounds driving this story are the same SKUs the research-peptide market already sells — nothing new hit the shelf, but a new buyer demographic just showed up, and the practical questions are the familiar ones:
- The Wolverine pairing is sold both ways. Vendors stock BPC-157 and TB-500 as separate vials and as pre-mixed blends; current blend pricing across suppliers is compared on /best/blend/wolverine-stack and in the Wolverine stack buying guide.
- KPV is the quiet third compound. Samluk's anti-inflammatory pick is one of the seven PCAC-advanced peptides; vendor options are in the KPV buying guide.
- COA verification is the whole game. Halioua's advice was two-part: involve a veterinarian, and use a reputable manufacturer. On the second point, quality varies enormously between sellers, and a third-party certificate of analysis is the only way to know what a vial contains. Our guide to verifying a peptide COA covers what to check.
- What owners reported spending. BI's subjects described costs from roughly $160 a month down to "well under $100." Per-vial pricing across suppliers is tracked on the deals page.
